

Publications of the International Breast Cancer Study Group

IBCSG 11-93

120. International Breast Cancer Study Group. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. *The Breast* 10 (Suppl 3): 130-138, 2001. (Trial 11-93)
126. Kitchen PRB, Smith HJ, Henderson MA, Goldhirsch A, Castiglione-Gertsch M, Coates AS, Gusterson B, Brown RW, Gelber RD, Collins JP. Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. *ANZ J Surg* 71:27-31, 2001. (Trials I-14)
155. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 365:1687-1717, 2005. (Trials II, III, VI, VII, IX, 11-93) (Journal impact factor 21.7)
167. Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravioli A for the IBCSG. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group Trials. *Cancer* 106:505-513, 2006. (Trials III, IV, VII, IX, 11-93, 12-93, 14-93) (Journal impact factor 4.4)
180. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS & Goldhirsch A for the IBCSG. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. *Ann Oncol* 18:701-708, 2007. (Trials VIII, IX, 11-15) (Journal impact factor 4.3)
209. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. *J Clin Oncol* 26:3006-3014, 2008. (Trials I-15) (Journal impact factor 13.6).
210. Regan MM, Pagani O, Walley B, Torrissi R, Perez EA, Francis P, Fleming GF, Price KN, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD for the SOFT/TEXT/PERCHE Steering Committee and the International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? *Ann Oncol* 19:1231-1241, 2008. (Trials 25-02, 26-02, 11-93) (Journal impact factor 5.2).
217. Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. *Breast Cancer Res Treat* 113:137-144, 2009. (Journal impact factor 4.5).
242. Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thürlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A. Breast Cancer Res Treat 123:303-310, 2010 (Trial 11-93) (Journal impact factor 4.7)
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer
279. Karlsson P, Cole BF, Chua BH, Price KN, Lindtner J, Collins JP, Kovács A, Thürlimann B, Crivellari D, Castiglione-Gertsch M, Forbes JF, Gelber RD, Goldhirsch A, Gruber G for the IBCSG. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. *Ann Oncol* 23: 2852-2858, 2012. (Trials I-IX, 11-14) (Journal impact factor 6.425).
280. Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Öhlschlegel C, Price KN, Gelber RD, Regan MM, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. *Ann Oncol* 23:2843-2851, 2012. (Trials I-IX, 11-14) (Journal impact factor 6.425).
439. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155,746 women in 151 trials. *Lancet* 2024;404(10461):1407-1418. doi: 10.1016/S0140-6736(24)01745-8. Epub 2024 Oct 12. (IBCSG VI, VIII, IX, 10-93, 11-93, 12a-93, 13-93, 14a-93, 15-95, 24-02, 25-02, 30-04, and BIG 1-98) (Journal Impact Factor 88.5).